There is no maximum time limit for taking Ozempic. The FDA approves semaglutide (the active ingredient in both Ozempic and Wegovy) for long-term use, and the official prescribing label includes no cutoff date or recommended stopping point. Most people who benefit from the medication are expected to continue it indefinitely, because the conditions it treats, type 2 diabetes and obesity, are chronic.
That said, “no time limit” doesn’t mean “take it forever without thinking about it.” How long you personally stay on Ozempic depends on how well it’s working, how you tolerate it, and what happens to your health markers over time. Here’s what the evidence says about long-term use, safety, and what to expect if you stop.
Why Long-Term Use Is the Default
Ozempic works by mimicking a gut hormone called GLP-1 that regulates blood sugar and appetite. It doesn’t cure diabetes or permanently reset your weight. It manages those conditions for as long as you take it, similar to how blood pressure medication controls hypertension without eliminating the underlying cause. The American Diabetes Association recommends reassessing diabetes medications every 3 to 6 months, but that guidance is about checking whether the drug is still the right fit, not about setting an end date.
Clinical trials have studied semaglutide for up to about 2.8 years (148 weeks) continuously. The largest cardiovascular outcomes trial, SUSTAIN 6, followed patients for a median of about two years and found sustained benefits throughout. In practice, many patients have now been on semaglutide for considerably longer than that, since the drug was first approved in 2017.
What Happens When You Stop
This is the part most people searching this question really want to know. A large systematic review published in The BMJ in 2025 analyzed 37 studies on weight changes after stopping weight management medications, including GLP-1 drugs. The findings were stark: people regained weight at an average rate of about 0.4 kilograms (roughly 0.9 pounds) per month after stopping. At that pace, the review projected a full return to pre-treatment weight within about 1.7 years of stopping.
Weight wasn’t the only thing that bounced back. Blood sugar levels, cholesterol, triglycerides, and blood pressure all trended back toward their original values and were projected to reach baseline within about 1.4 years after stopping. This pattern is the main reason doctors typically recommend staying on the medication rather than using it as a short-term fix.
Long-Term Safety Profile
For a drug people may take for years or decades, safety data matters enormously. The two concerns that get the most attention are thyroid cancer and pancreatitis.
On thyroid cancer: animal studies found that GLP-1 drugs caused thyroid tumors in rodents, which is why Ozempic carries a boxed warning about medullary thyroid carcinoma. In human clinical trials, however, the signal has been minimal. Across the entire SUSTAIN trial program involving nearly 6,000 semaglutide-treated patients, two cases of thyroid malignancy occurred in the treatment group versus one in the comparison group. None were the medullary type flagged in animal studies. Blood tests measuring calcitonin, a marker for medullary thyroid cancer, showed no meaningful difference between treatment and comparison groups.
On pancreatitis and pancreatic cancer: a meta-analysis combining data from all major GLP-1 cardiovascular outcomes trials found no statistically significant increase in risk for either condition. The hazard ratios were 1.05 for pancreatitis and 1.12 for pancreatic cancer, both with confidence intervals that crossed 1.0 (meaning the results were consistent with no effect). One caveat: the longest follow-up periods in these trials ranged from about 1.3 to 5.4 years, which may not be long enough to detect very slow-developing cancers.
The most common long-term side effects remain gastrointestinal: nausea, vomiting, diarrhea, and constipation. For most people these are worst during the dose-escalation phase and improve over time, but some experience persistent stomach issues that lead them to discontinue.
What Your Doctor Monitors Over Time
Staying on Ozempic long-term means periodic check-ins, not just refilling prescriptions. If you have type 2 diabetes, expect an A1C blood test at least twice a year to confirm the drug is still controlling your blood sugar effectively. Your doctor will also likely ask you to monitor blood sugar at home.
Kidney function tests (blood or urine) are part of routine monitoring because GLP-1 drugs can occasionally affect the kidneys, particularly if dehydration occurs from nausea or vomiting. If you have a history of diabetic eye disease, your eye health may also be tracked more closely, since rapid blood sugar improvements can temporarily worsen diabetic retinopathy in some people.
Reasons You Might Stop or Switch
The American Diabetes Association identifies several legitimate reasons to discontinue or change a diabetes medication: it’s no longer working well enough, you’re experiencing side effects you can’t tolerate, a new health condition makes it unsafe, or the cost becomes unmanageable. Supply shortages, which have affected Ozempic intermittently, are another practical reason people sometimes stop.
If you’re considering stopping Ozempic, the key thing to plan for is the rebound effect described above. Some doctors recommend a gradual dose reduction rather than an abrupt stop, and intensifying lifestyle changes (diet, exercise) before and during the transition. Switching to a different medication in the same class is another option if the issue is side effects rather than wanting to stop treatment altogether.
How Long Most People Actually Stay On It
Real-world data from Japan found that about 83% of patients taking the weekly semaglutide injection were still on it at 12 months. That’s a relatively high persistence rate compared to many chronic medications, but it still means roughly one in five people stopped within the first year, whether due to side effects, cost, supply issues, or personal choice. Long-term persistence data beyond one year is still limited in real-world settings, though it will grow as the drug’s user base ages.
The bottom line: Ozempic is designed and approved for use that continues as long as it’s helping you and you’re tolerating it well. There’s no built-in expiration on treatment. But it does require ongoing monitoring, and stopping it will likely reverse most of the metabolic benefits it provided within a year or two.